DGAP-News: STRATEC Biomedical AG / Key word(s): Final Results
STRATEC achieves higher sales and improved profitability in 2015
Birkenfeld, April 14, 2016
STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX) today announced the final audited results of the STRATEC Group for the financial year ending December 31, 2015, with the publication of its 2015 Annual Report. These figures prepared in line with International Financial Reporting Standards (IFRS) have been audited and granted an unqualified audit opinion.
bps = basis points
Additionally, the company continued to receive a high volume of progress payments for development services. These projects and subsequent market launches are expected to generate the growth planned over the coming years.
The share of sales attributable to service parts increased from 23.4% in 2014 to 24.3% in 2015.
EBIT increased by 11.7% from EUR 24.1 million in the previous year to EUR 26.9 million in the 2015 financial year, representing an EBIT margin of 18.3%. Consolidated net income grew correspondingly by 11.7% to EUR 22.1 million, and earnings per share increased by 11.3% to EUR 1.87.
Acquisition of Diatron
Diatron supplies analyzer systems and complementary products such as consumables and services for use in human and veterinary diagnostics to more than 100 countries. Among its customers are well-known life science companies with global operations. In 2015 the company generated sales equivalent to around EUR 34 million with profitability comparable to that of the STRATEC Group. The acquisition is expected to be make a positive contribution to Group earnings in 2016.
Pending approval from the Annual General Meeting, shareholders can thus anticipate an increase in the dividend for the twelfth consecutive time since dividends were first paid in 2004. We thus intend to maintain our continuity-based dividend policy, which provides for a distribution quota of between 40 and 60%. STRATEC continues to focus on internal and external growth opportunities. This may result in temporary deviations from the distribution quota. These opportunities may take the form of acquisitions or potential up-front financing for major projects.
Development in personnel
In order to keep pace with the anticipated continued growth, production capacities at STRATEC's location in Switzerland were expanded during 2015. At the location in Romania, construction of a new building began towards the end of 2015, and the employees at the site in the United Kingdom moved to a modern, larger building as the capacity of the old space had been reached.
STRATEC will continue to be in need of qualified personnel, especially in development.
STRATEC's Board of Management has an interest in long-term staff retention. For this reason, employees were given the opportunity in the 2015 financial year to participate in the success of the company through an employee participation program, further details of which can be found in our Annual Report.
Projects and other developments
For 2016 we expect the proportion of sales from spare parts to remain in line with the high level achieved in 2015, partly driven by the increased need for spare parts for recently developed, more complex systems.
The Data Management business unit developed very positively in the 2015 financial year, especially due to an order from a new major customer.
The range of offerings and thus also the foundation for growth of STRATEC will continue to be strengthened through targeted company acquisitions.
2015 Annual Report
The Annual General Meeting of STRATEC Biomedical AG will be held in Pforzheim on June 9, 2016. The invitation to the Annual General Meeting will be forwarded to STRATEC shareholders in good time ahead of the Annual General Meeting.
Further information can be obtained from:
|Company:||STRATEC Biomedical AG|
|Phone:||+49 (0)7082 7916 0|
|Fax:||+49 (0)7082 7916 999|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Terminbörse EUREX|
|End of News||DGAP News Service|